OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Broadening horizons: the role of ferroptosis in cancer	1609
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	1037
Immunotherapies for hepatocellular carcinoma	914
PD-L1 as a biomarker of response to immune-checkpoint inhibitors	838
Liquid biopsy enters the clinic — implementation issues and future challenges	736
Unlocking the potential of antibody–drug conjugates for cancer therapy	625
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	609
The emerging roles of circRNAs in cancer and oncology	608
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines	596
Clinical and therapeutic relevance of cancer-associated fibroblasts	590
Immune-checkpoint inhibitors: long-term implications of toxicity	514
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways	461
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070	446
Harnessing cytokines and chemokines for cancer therapy	446
Advancing therapy for osteosarcoma	438
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	405
Long-term outcomes following CAR T cell therapy: what we know so far	394
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	389
Clinical relevance of tumour-associated macrophages	368
Targeting drugs to tumours using cell membrane-coated nanoparticles	355
Clinical implications of T cell exhaustion for cancer immunotherapy	351
Rising incidence of early-onset colorectal cancer — a call to action	348
Predicting cancer outcomes with radiomics and artificial intelligence in radiology	331
The global burden of lung cancer: current status and future trends	314
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome	306

Understanding and overcoming resistance to PARP inhibitors in cancer therapy	287
Senescence and cancer — role and therapeutic opportunities	284
Intratumoural administration and tumour tissue targeting of cancer immunotherapies	281
Nasopharyngeal carcinoma: an evolving paradigm	277
Therapeutic targeting of the hypoxic tumour microenvironment	254
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics	240
Protein degraders enter the clinic — a new approach to cancer therapy	232
The current state of the art and future trends in RAS-targeted cancer therapies	231
Is early-onset cancer an emerging global epidemic? Current evidence and future implications	215
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma	215
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	210
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	209
The implications of IDH mutations for cancer development and therapy	204
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention	200
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?	200
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer	199
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains	198
The emerging role of photoacoustic imaging in clinical oncology	195
Therapy with oncolytic viruses: progress and challenges	192
Fundamentals and developments in fluorescence-guided cancer surgery	178
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC	174
Towards precision medicine for AML	167
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy	167
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm	166
Gut microbiota in colorectal cancer development and therapy	165
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy	164
Advancing therapy for neuroblastoma	162
Tumour burden and efficacy of immune-checkpoint inhibitors	160
Immunogenicity of CAR T cells in cancer therapy	158
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	156
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion	153
The emerging roles of γδ T cells in cancer immunotherapy	149
The blood–tumour barrier in cancer biology and therapy	149
The nuclear export protein XPO1 — from biology to targeted therapy	145
Radiotheranostics in oncology: current challenges and emerging opportunities	143
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours	140
Circulating tumour DNA — looking beyond the blood	138
Neoadjuvant therapy for pancreatic cancer	138
Towards clinical translation of FLASH radiotherapy	134
Precision oncology in metastatic colorectal cancer — from biology to medicine	129
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment	116
International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer	116
Novel approaches to target the microenvironment of bone metastasis	113
Emerging evidence for adapting radiotherapy to immunotherapy	112
The roles and implications of RNA m6A modification in cancer	112
Thermal immuno-nanomedicine in cancer	110
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	110
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn	103
The multiple roles of LDH in cancer	100
Humanized mouse models for immuno-oncology research	100

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials	100
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice	99
Advances in the clinical management of uveal melanoma	93
Circulating tumour cells for early detection of clinically relevant cancer	88
Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management	87
Criteria for the translation of radiomics into clinically useful tests	86
Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects	84
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide	78
Exploring the next generation of antibody–drug conjugates	77
Integrated MRI-guided radiotherapy — opportunities and challenges	76
At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy	74
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine	72
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	70
Beneficial autoimmunity improves cancer prognosis	66
Predicting tumour radiosensitivity to deliver precision radiotherapy	66
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	63
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy	62
Mitigating acute chemotherapy-associated adverse events in patients with cancer	60
Towards precision oncology with patient-derived xenografts	60
The immune landscape of common CNS malignancies: implications for immunotherapy	60
Harnessing big data to characterize immune-related adverse events	57
Cholangiocarcinoma — novel biological insights and therapeutic strategies	56
New treatment strategies for advanced-stage gastrointestinal stromal tumours	56
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC	56
Biomarkers for immunotherapy of hepatocellular carcinoma	55
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	54
Systemic therapy for early-stage breast cancer: learning from the past to build the future	50
Advancing CAR T cell therapy through the use of multidimensional omics data	50
Myeloid-derived suppressor cells in cancer and cancer therapy	46
The oligometastatic spectrum in the era of improved detection and modern systemic therapy	45
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma	43
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells	41
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	40
Rare molecular subtypes of lung cancer	39
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy	39
Barriers in access to oncology drugs — a global crisis	39
Global epidemiology of epithelial ovarian cancer	38
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment	38
The clinical development of antibody–drug conjugates — lessons from leukaemia	37
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer	36
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	35
Advances in the management of peritoneal malignancies	35
Heterogeneity and treatment landscape of ovarian carcinoma	34
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	33
Molecular tumour boards — current and future considerations for precision oncology	33
Immunotherapy approaches for malignant pleural mesothelioma	32
Lung cancer in patients who have never smoked — an emerging disease	31
Improving outcomes in patients with oesophageal cancer	28
Drug-tolerant persister cells in cancer: the cutting edges and future directions	27
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors	27
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours	26
Dendritic cells as orchestrators of anticancer immunity and immunotherapy	25
Advancing oncolytic virus therapy by understanding the biology	24
Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?	24
TAM family kinases as therapeutic targets at the interface of cancer and immunity	24
Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century	24
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions	24